Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous mon
- PDF / 611,894 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 60 Downloads / 166 Views
RETINAL DISORDERS
Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up Hamid Hosseini 1 & Gilad Rabina 1,2 & Moritz Pettenkofer 1 & Adrian Au 1 & Ismael Chehaibou 1,3 & Gad Heilweil 1 & Adam J. Weiner 1 & Michael Ip 4 & Anat Loewenstein 2 & Steven D. Schwartz 1 Received: 25 June 2020 / Revised: 1 October 2020 / Accepted: 20 November 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose To describe the clinical characteristics and visual outcomes of neovascular age-related macular degeneration (NVAMD) patients with irregular pigment epithelium detachment (PED) and non-resolving subretinal fluid (SRF) despite continuous monthly injections of anti-vascular endothelial growth factor (VEGF). Methods This is a retrospective case series, including NV-AMD patients treated in a tertiary academic practice. Inclusion criteria were NV-AMD diagnosis, with irregular PED, and non-resolving SRF treated with continuous monthly anti-VEGF intravitreal injections. Data collection included best corrected visual acuity (BCVA), central macular thickness (CMT), sub-foveal choroidal thickness (SFCT), and type and location of PED as seen on optical coherence tomography (OCT). Results A total of 738 patients with NV-AMD underwent anti-VEGF injections during the follow-up period and 20 eyes of 19 patients (14 females and 5 males) met the inclusion criteria. Average age was 81.7 ± 6.6 years, mean follow-up time was 32.1 ± 23.5 months, and mean number of injections was 31.3 ± 24.2. Mean VA was 0.26 ± 0.21 logMAR (Snellen 20/36) at baseline versus 0.20 ± 0.23 logMAR (Snellen 20/32) at the end of the follow-up (P = 0.28). All eyes presented with sub-foveal, type 1 macular neovascularization (MNV). Average sub-foveal choroidal thickness changed from 189.70 ± 68.46 μm at baseline to 169.00 ± 63.06 μm (P < 0.001) at last follow-up. Conclusion Patients with type 1 NV-AMD, irregular PED, and non-resolving SRF and under continuous treatment of monthly anti-VEGF injections may maintain good visual acuity after long period of time. Keywords Age-related macular degeneration . Subretinal fluid . Anti-VEGF . Macular neovascularization . Non-resolving
Hamid Hosseini and Gilad Rabina share equal contribution * Gilad Rabina [email protected] 1
Retina Division, Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
2
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3
Ophthalmology Department, AP-HP, Hôpital Lariboisière, Université de Paris, F-75010 Paris, France
4
Doheny Eye Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA
Graefes Arch Clin Exp Ophthalmol
Key messages Anti-VEGF treatment improves visual acuity by reducing IRF, SRF and PED size. Residual IRF have a
Data Loading...
